PQQ (Pyrroloquinoline Quinone)

Plain-language summaryIntrigue 60 / 100

PQQ (pyrroloquinoline quinone) is a redox cofactor found in plants and bacteria that may stimulate mitochondrial biogenesis (creation of new mitochondria). Sold as a longevity and energy supplement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

A mature bacterial redox cofactor with an interesting mitochondrial story that human evidence never fully validated

Look, PQQ has been in the research conversation long enough that calling it a frontier compound is a stretch. The bacterial dehydrogenase work goes back to the 1980s, and the mammalian mitochondrial biogenesis story picked up in the early 2000s after some elegant deficiency-repletion work in mice. Its a genuinely interesting setup. The problem is what happened next.

The mechanism is the compound’s strongest asset. PQQ cycles through redox states faster than vitamin C and with more catalytic capacity than most dietary antioxidants, and the downstream signaling through NRF2 and PGC-1alpha gives it more to say than just “antioxidant.” The biogenesis angle is real: chronic PQQ deficiency in rodents produces mitochondrial dysfunction phenotypes that reverse on repletion. We like that the mechanism has multiple plausible entry points, and the chemistry is genuinely unusual for a dietary-origin compound. That’s worth noting.

What we dont like: fifteen-plus years of research interest and the human trials are still small, the effect sizes modest, the replication incomplete. Cognitive function, fatigue, and cardiovascular endpoints have all been probed in small cohorts with some signal, but not the kind of signal that reorganizes a research program. The NRF2 and PGC-1alpha pathways are crowded now. Urolithin A, NAD precursors like nicotinamide riboside, and several mitochondria-targeted peptides have moved into the same territory with arguably cleaner pharmacology and stronger human translation. PQQ doesnt clearly win any dimension of that comparison.

The bench utility is real but specific. If your program involves dietary-origin redox cofactors in mitochondrial function, or probing PGC-1alpha activation by a small molecule with a plant-food sourcing history, PQQ earns its place in the toolkit. The BioPQQ trademarked product has reasonable characterization and reproducible sourcing, which matters for experimental consistency. But as a general mitochondrial biogenesis probe, theres more compelling options with cleaner pharmacology and better-defined target engagement.

Honestly, this compound fits the profile of many redox and mitochondrial-adjacent supplements that generated real excitement a decade ago and have since settled into the “interesting but unproven” column. The mechanism remains incompletely characterized, which after this many years of study is more liability than intrigue. Worth tracking for programs specifically touching dietary-origin redox biology or NRF2 activation in aging contexts, not a compound to build a research program around.

Novelty: 32
Mechanism promise: 45
In-category differentiation: 28
Evidence quality: 33
Translational signal: 35
Research bench value: 42

Rationale PQQ earns points on mechanism interest (NRF2 + PGC-1alpha + high-capacity redox cycling is a real multi-target story) but loses heavily on novelty (the mitochondrial biogenesis angle is fifteen-plus years old), thin human evidence with modest effect sizes, and weak differentiation in a now-crowded mitochondrial space. Bench utility exists but is narrow and not irreplaceable.

Redox cofactor

A bacterial redox cofactor and putative mitochondrial biogenesis enhancer found in trace amounts in plant foods, sold as a dietary supplement.

Abstract

Pyrroloquinoline quinone (PQQ; CAS 72909-34-3; molecular formula C14H6N2O8; molecular weight 330.21) is a redox cofactor present in bacterial dehydrogenases and in trace amounts in plant foods (kiwi, parsley, green tea, fermented soy). PQQ has been studied as a putative mitochondrial biogenesis stimulant; chronic dietary PQQ deficiency in mice produces mitochondrial dysfunction phenotypes that are reversed by repletion. The compound has been studied for cognitive function, fatigue, and cardiovascular endpoints in small human trials with modest effect sizes. Mechanism is incompletely characterized; proposed activities include direct redox cycling, NRF2 pathway activation, and PGC-1alpha-mediated mitochondrial biogenesis. Doses are typically 10 to 40 mg per day. The compound is sold as a dietary supplement (BioPQQ).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-119Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.